MedTech Dive

Edwards receives FDA approval for mitral valve replacement system

The Sapien M3 device is the first approved mitral regurgitation treatment to use a transseptal approach, Edwards said.
BioWorld

Edwards’ Pascal device shows well against Abbott’s Mitraclip at TCT

One of the biggest stories coming out of Transcatheter Cardiovascular Therapeutics’ annual meeting in Boston this weekend focuses on the success of Edwards Lifesciences Corp.’s freshly FDA-approved ...
Nasdaq

CLASP IID ONE-YEAR DATA CONFIRM SAFETY AND EFFICACY OF EDWARDS PASCAL SYSTEM FOR DEGENERATIVE MITRAL REGURGITATION

SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two ...
AOL

Abbott Labs, Edwards Lifesciences Settle Heart Device Patent Disputes

Abbott Laboratories (ABT) announced on Monday that it has reached an agreement with Edwards Lifesciences Corp. (EW) to settle all outstanding patent disputes related to heart valve medical devices or ...